Drug Profile


Alternative Names: Caprolactam-azabenzimidazolone - Merck; MK-0974; Telcagepant potassium

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antimigraines; Piperidines
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Endocrine disorders; Migraine

Most Recent Events

  • 29 Jul 2011 Discontinued - Phase-I for Migraine in Belgium (PO)
  • 29 Jul 2011 Discontinued - Phase-II/III for Migraine in USA (PO)
  • 29 Jul 2011 Discontinued - Phase-III for Migraine in Austria (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top